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PilOBJECTIVES The aim of this study was to investigate the safety and efficacy of biodegradable-polymer sirolimus-
eluting stents (BP-SES) compared with durable-polymer everolimus-eluting stents (DP-EES) in patients with ST-segment
elevation myocardial infarction (STEMI).
BACKGROUND Primary percutaneous coronary intervention (PCI) is an effective treatment for patients with STEMI,
and long-term outcomes are determined by the safety and efficacy profile of the newest generation drug-eluting stents.
METHODS BIOSTEMI (A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a
Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Under-
going Primary Percutaneous Coronary Intervention) was an investigator-initiated, multicenter, assessor-blind, random-
ized superiority trial using Bayesian methods. Patients with STEMI undergoing primary PCI within 24 h of symptom onset
were randomized in a 1:1 ratio to receive BP-SES (n ¼ 649) or DP-EES (n ¼ 651). The primary endpoint was target lesion
failure (TLF), a composite of cardiac death, target vessel myocardial reinfarction, and clinically indicated target lesion
revascularization (TLR) at 2 years.
RESULTS Between April 2016 and March 2018, 1,300 patients were included. Baseline characteristics were comparable
between the 2 treatment groups. Follow-up through 2 years was complete in 1,221 patients (94%). At 2 years, TLF
occurred in 33 patients (5.1%) treated with BP-SES and in 53 patients (8.1%) treated with DP-EES (rate ratio: 0.58; 95%
Bayesian credible interval: 0.40 to 0.84; posterior probability of superiority ¼ 0.998). The difference was driven by a
lower incidence of clinically indicated TLR in patients treated with BP-SES compared with DP-EES (2.5% vs. 5.1%; rate
ratio: 0.52; 95% Bayesian credible interval: 0.30 to 0.87; posterior probability of superiority ¼ 0.993). There were no
significant differences in rates of cardiac death, target vessel myocardial reinfarction, and definite stent thrombosis
between the 2 treatment arms.
CONCLUSIONS In patients with STEMI undergoing primary PCI, BP-SES were superior to DP-EES with respect to TLF at
2 years. The difference was driven by lower rates of ischemia-driven TLR. (A Comparison of an Ultrathin Strut
Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With
Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
[BIOSTEMI]; NCT02579031) (J Am Coll Cardiol Intv 2021;14:639–48) © 2021 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2020.12.011
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640P ercutaneous coronary intervention(PCI) is an effective strategy to restoremyocardial perfusion in patients with
acute myocardial infarction that improves
prognosis by reducing final infarct size and
the risk for infarct-vessel reocclusion (1).
Drug-eluting stents (DES) mitigate the need
for repeat revascularizations compared with
bare-metal stents (2,3) and represent the
current standard of care (4).
Recent refinements of newer generation
DES involve the reduction of strut thickness
of the metallic stent platform and the use of
biodegradable polymers as a carrier for the
antiproliferative substance. These improve-
ments in stent design mitigate arterial injury,SEE PAGE 649inflammation, and thrombogenicity, facilitate
endothelialization, and reduce neointimal hyperpla-
sia (5). A robust body of evidence supporting the
noninferiority of biodegradable-polymer sirolimus-
eluting stents (BP-SES) compared with second-
generation DES (6–9) has recently been challenged
by accumulating evidence indicating superiority
compared with durable-polymer everolimus-eluting
stents (DP-EES) with regard to device-oriented clin-
ical outcomes in patients with chronic and acute
coronary syndromes (10–12).
Acute myocardial infarction confers an increased
risk for stent-related adverse events due to an exac-
erbated inflammatory response resulting in delayed
arterial healing (13,14). The BIOSTEMI (A Comparison
of an Ultrathin Strut Biodegradable Polymer
Sirolimus-Eluting Stent With a Durable Polymer
Everolimus-Eluting Stent for Patients With Acute
ST-Segment Elevation Myocardial Infarction Under-
going Primary Percutaneous Coronary Intervention)
trial was the first randomized trial comparing 2
contemporary DES in patients with acute myocardial
infarction and demonstrated the superiority of
BP-SES versus DP-EES with regard to target lesion
failure at 1 year (12). Here, we report the final 2-year
outcomes of the BIOSTEMI trial.
METHODS
STUDY DESIGN AND PATIENTS. The BIOSTEMI trial was
an investigator-initiated, single-blind, multicenter,s attest they are in compliance with human studies committe
and Food and Drug Administration guidelines, including patien
thor Center.
received September 28, 2020; revised manuscript received Decerandomized trial investigating the hypothesis that BP-
SES are superior to DP-EES in patients undergoing
primary PCI for ST-segment elevation myocardial
infarction (STEMI) at 10 interventional cardiology
centers in Switzerland. The rationale of the trial as well
as details of study conduct, randomization, blinding,
data management, and data monitoring have been
described previously (15). In brief, subjects with STEMI
referred for PCI within 24 h of symptom onset qualified
for study enrollment if they had at least 1 culprit cor-
onary lesion suitable for stent implantation. Patients
or the public were not involved in the design, conduct,
reporting, or dissemination plans of our research. The
study was approved by the institutional ethics com-
mittees of all participating sites and complied with the
Declaration of Helsinki. All patients conscious at the
time of intervention provided written informed con-
sent; preliminary consent by proxy was accepted for
unconscious patients and had to be confirmed by the
patients as soon as possible. The trial is registered with
ClinicalTrials.gov (NCT02579031).DEVICES AND PROCEDURES. The experimental stent
(Orsiro, Biotronik, Bülach, Switzerland) combines a
cobalt-chromium platform (60-mm strut thickness for
stent diameters up to 3.0 mm, 80-mm strut thickness
for stent diameters >3.0 mm) covered with an
amorphous hydrogen-rich, silicon-carbide layer
(PROBIO, Biotronik) with an asymmetrical biodegrad-
able poly-L-lactic acid (PLLA) polymermatrix releasing
sirolimus at a dose of 1.4 mg/mm2 stent surface, which
degrades over a period of 12 to 24 months (16). The
control stent (Xience Prime/Xpedition, Abbott
Vascular, Santa Clara, California) is based on a cobalt-
chromium platform with a strut thickness of 81 mm
that releases everolimus from a durable polymer
(poly-n-butyl-methacrylate and copolymer of vinyli-
dene fluoride and hexafluoropropylene).
ENDPOINT DEFINITIONS AND FOLLOW-UP. The
primary endpoint of the trial was target lesion failure,
a composite of cardiac death, target vessel myocardial
reinfarction, and clinically indicated target lesion
revascularization as assessed at 12 months, and has
been reported previously (12). Follow-up at 2 years
was performed by use of a clinical visit or aes and animal welfare regulations of the authors’
t consent where appropriate. For more information,
mber 3, 2020, accepted December 7, 2020.
FIGURE 1 Patient Flow According to the Consolidated Standards of Reporting Trials Statement
BIOSCIENCE ¼ Sirolimus-Eluting Stents With Biodegradable Polymer Versus an Everolimus-Eluting Stents; BIOSTEMI ¼ A Comparison of an Ultrathin Strut Biode-
gradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction
Undergoing Primary Percutaneous Coronary Intervention; BMS ¼ bare-metal stent(s); BP-SES ¼ biodegradable-polymer sirolimus-eluting stent(s); CABG ¼ coronary
artery bypass grafting; DES ¼ drug-eluting stent(s); DP-EES ¼ durable-polymer everolimus-eluting stent(s).
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641standardized telephone interview. All definitions
have been described previously (12). Any death,
reinfarction, revascularization, stent thrombosis,
cerebrovascular accident, and bleeding events were
independently adjudicated by a clinical events
committee blinded to treatment arm allocation.
STATISTICAL ANALYSIS. Consistent with the pri-
mary endpoint analysis at 1 year (12), we used
Bayesian statistical methods with robustified priors
incorporating historical data from 407 patients with
acute STEMI who had been enrolled in the BIOSCI-
ENCE (Sirolimus-Eluting Stents With Biodegradable
Polymer Versus an Everolimus-Eluting Stents) trial
(17) to assess the endpoint results at 2 years. All ana-
lyses were done with the individual subject as the unit
of analysis and according to the intention-to-treatprinciple. Follow-up time was censored at the time
of an event, loss to follow-up, or end of the planned
follow-up at 2 years, whichever occurred first.
Bayesian log Poisson models incorporating histori-
cal data from the BIOSCIENCE trial were used for the
purpose of the present analysis (17). We estimated the
log incidence rates of all clinical endpoints from the
BIOSCIENCE trial (n ¼ 407) in each of the 2 study arms.
We used Bayesian log Poisson models with minimally
informative priors (m ¼ 0, s ¼ 0.111) and an offset term
(log of the time at risk) to model the rates. Then we
used the posterior mean and SD of the log incidence
rates in BIOSCIENCE as informative priors for the
analysis of BIOSTEMI endpoints at 2 years. For each
endpoint, the robust prior was a 50:50 mixture be-
tween the historical informative prior (m ¼ posterior
TABLE 1 Medications at 2 Years of Follow-Up
Biodegradable-Polymer
Sirolimus-Eluting
Stents (n ¼ 590)
Durable-Polymer
Everolimus-Eluting
Stents (n ¼ 603) p Value
At 1-yr follow-up
Aspirin 563 (95.4) 582 (96.5) 0.378
Clopidogrel 61 (10.3) 65 (10.8) 0.851
Prasugrel 179 (30.3) 202 (33.5) 0.264
Ticagrelor 268 (45.4) 255 (42.3) 0.294
Any dual-antiplatelet treatment 485 (82.2) 501 (83.1) 0.703
Oral anticoagulant agents 14 (2.4) 14 (2.3) 1.000
Novel oral anticoagulant agents 26 (4.4) 32 (5.3) 0.503
Any antithrombotic treatment 40 (6.8) 45 (7.5) 0.655
Statins 524 (88.8) 557 (92.4) 0.037
ACE inhibitors 354 (60.0) 372 (61.7) 0.554
Beta-blockers 417 (70.7) 444 (73.6) 0.272
At 2-yr follow-up
Aspirin 535 (91.9) 536 (91.9) 1.000
Clopidogrel 15 (2.6) 23 (3.9) 0.248
Prasugrel 14 (2.4) 18 (3.1) 0.591
Ticagrelor 32 (5.5) 21 (3.6) 0.125
Any dual-antiplatelet treatment 49 (8.4) 51 (8.7) 0.917
Oral anticoagulant agents 16 (2.7) 17 (2.9) 1.000
Novel oral anticoagulant agents 26 (4.5) 39 (6.7) 0.125
Any antithrombotic treatment 42 (7.2) 55 (9.4) 0.203
Statins 513 (88.1) 506 (86.8) 0.536
ACE inhibitors 314 (54.0) 325 (55.7) 0.556
Beta-blockers 374 (64.3) 365 (62.6) 0.584
Values are n (%). 1 patient in the biodegradable-polymer sirolimus-eluting stent arm refused to give medication
information.
ACE ¼ angiotensin-converting enzyme.
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642mean [BIOSCIENCE], s ¼ posterior standard deviation
[BIOSCIENCE]) and a vague prior (m ¼ 0, s ¼ 0.111) on
the basis of Bernoulli distributions. By use of Bayesian
log Poisson models with time at risk fitted as an offset,
we estimated the incidence rate in both arms for all
endpoints at 2 years. The use of robustified priors
efficiently controlled the type I error rate by down-
weighting the contribution of historical information
from the BIOSCIENCE trial if it turned out to be
inconsistent with the information collected in the
BIOSTEMI trial. Rate ratios (RRs) are reported as the
median of the Bayesian posterior distribution, and
associated 95% Bayesian credible intervals are re-
ported as the 2.5th and 97.5th percentiles of the
Bayesian posterior distribution. Within the framework
of this analysis, BCIs were interpreted similarly to
frequentist confidence intervals (18).
We performed pre-specified subgroup analyses
according to the presence or absence of diabetes and
multivessel disease at baseline and post hoc sub-
group analyses according to age, sex, body mass
index, vessel diameter, lesion length, and renal
failure. We also conducted a post hoc landmark
analysis with the landmark set at 1 year for the pri-
mary endpoint and individual components of theprimary endpoint. Subgroup and landmark analyses
were conducted using the same approach as in the
main analyses. For the subgroup analyses, robusti-
fied historical priors were constructed by analysis of
the primary endpoint in each subgroup of patients in
the BIOSCIENCE trial with acute STEMI. For the
landmark analyses, robustified historical priors were
constructed by analysis of the given endpoint in
each period (before or after landmark) in the
BIOSCIENCE trial with acute STEMI. These
subgroup-specific or period-specific robustified his-
torical priors were used as priors to analyze the data
from the BIOSTEMI patients. For descriptive pur-
poses, we derived Kaplan-Meier curves for patients
included in the acute STEMI subgroup of the
BIOSCIENCE trial and in the BIOSTEMI trial sepa-
rately and combined. Full details including model
equations and graphical representations of the priors
are provided in the statistical analysis plan of the
BIOSTEMI trial. Statistical analyses were conducted
in R Studio version 3.6.2 (R Foundation for Statisti-
cal Computing, Vienna, Austria) and Stata 15 (Stata-
Corp, College Station, Texas).
RESULTS
Between April 26, 2016, and March 9, 2018, 1,300
patients with 1,623 lesions were randomly allocated
to treatment with BP-SES (n ¼ 649, 817 lesions) or DP-
EES (n ¼ 651, 806 lesions). At 2 years, follow-up data
were available for 610 of 649 patients receiving BP-
SES (94.0%) and 611 of 651 patients receiving DP-
EES (93.9%). The median duration of follow-up was
730 days (interquartile range: 710 to 730 days). The
trial profile at completion of the BIOSTEMI trial at 2
years is displayed in Figure 1.
Baseline clinical, angiographic, and procedural
characteristics have been reported previously (12).
The mean age of patients was 62.2  11.8 years in the
experimental arm and 63.2  11.8 years in the control
arm; 136 patients (21%) treated with BP-SES and 174
patients (27%) treated with DP-EES were female.
Medications at 2-year follow-up are summarized in
Table 1 and showed no significant differences
between groups. At 2 years, the composite endpoint,
target lesion failure, occurred in 33 patients (5.1%)
treated with BP-SES and in 53 patients (8.1%) treated
with DP-EES (RR: 0.58; 95% BCI: 0.40 to 0.84;
posterior probability of superiority ¼ 0.998) (Table 2,
Central Illustration). The difference remained statis-
tically significant after the exclusion of historical
information from the BIOSCIENCE trial (RR: 0.62; 95%
BCI: 0.40 to 0.96; posterior probability of
superiority ¼ 0.985) (Table 2 and Supplemental
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Target lesion failure* 33 (5.1) 53 (8.1) 0.58 (0.40–0.84) 0.998 0.62 (0.40–0.96) 0.985
Cardiac death 19 (2.9) 21 (3.2) 0.77 (0.44–1.35) 0.823 0.91 (0.49–1.69) 0.614
Target vessel MI 10 (1.5) 13 (2) 0.67 (0.33–1.34) 0.875 0.77 (0.33–1.75) 0.731
Clinically indicated TLR 16 (2.5) 33 (5.1) 0.52 (0.30–0.87) 0.993 0.48 (0.26–0.86) 0.993
All-cause death 27 (4.2) 25 (3.8) 1.02 (0.64–1.63) 0.471 1.09 (0.63–1.89) 0.376
MI 24 (3.7) 20 (3.1) 1.01 (0.59–1.71) 0.491 1.20 (0.67–2.20) 0.267
Q-wave 5 (0.8) 5 (0.8) 0.73 (0.25–2.02) 0.727 1.01 (0.30–3.39) 0.495
Non-Q-wave 19 (2.9) 16 (2.5) 1.06 (0.58–1.93) 0.423 1.20 (0.62–2.38) 0.295
Repeat revascularization 35 (5.4) 52 (8) 0.67 (0.46–0.96) 0.985 0.67 (0.43–1.02) 0.969
Any TLR 18 (2.8) 34 (5.2) 0.54 (0.32–0.89) 0.992 0.53 (0.29–0.92) 0.989
Any TVR 22 (3.4) 41 (6.3) 0.58 (0.37–0.89) 0.994 0.53 (0.31–0.88) 0.993
Clinically indicated TVR 20 (3.1) 40 (6.1) 0.56 (0.35–0.87) 0.995 0.50 (0.29–0.84) 0.996
Target vessel failure† 39 (6.0) 61 (9.4) 0.61 (0.43–0.86) 0.998 0.63 (0.42–0.94) 0.988
Death, MI, or any repeat revascularization‡ 65 (10.0) 77 (11.8) 0.81 (0.61–1.08) 0.929 0.84 (0.60–1.17) 0.849
Definite stent thrombosis 9 (1.4) 12 (1.8) 0.73 (0.30–1.69) 0.771 0.76 (0.31–1.77) 0.739
Definite or probable stent thrombosis 13 (2.0) 15 (2.3) 0.72 (0.38–1.44) 0.837 0.87 (0.41–1.84) 0.642
BARC bleeding events types 3 to 5 26 (4.0) 24 (3.7) 0.92 (0.58–1.59) 0.625 1.10 (0.63–1.92) 0.372
Values are n (%), unless otherwise indicated. *Primary endpoint, defined as the composite of cardiac death, target vessel Q-wave or non-Q-wave MI, and clinically indicated TLR. †Defined as the composite of
cardiac death, any Q-wave or non-Q-wave MI, and any TVR. ‡Patient-oriented composite endpoint.
BARC ¼ Bleeding Academic Research Consortium; BCI ¼ Bayesian credibility interval; MI ¼ myocardial infarction; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization.
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643Figure 1) and was driven by a lower incidence of
clinically indicated target lesion revascularization in
patients treated with BP-SES (2.5%) compared with
DP-EES (5.1%) (RR: 0.52; 95% BCI: 0.30 to 0.87; pos-
terior probability of superiority ¼ 0.993).
The findings for target lesion failure were consis-
tent across various patient subsets in a stratified
analysis (Figure 2). Patients presenting with multi-
vessel disease had a particular benefit of treatment
with BP-SES with a significant interaction (Bayesian
posterior probability ¼ 0.994). We found a consistent
treatment effect between BP-SES and DP-EES with
respect to the occurrence of TLF at 2 years
irrespective of stent diameter #3.0 mm (Figure 2)
or #2.5 mm (Supplemental Table 1). Event rates of
target lesion failure documented at each participating
site are provided in Supplemental Table 2.
Landmark analyses of clinical endpoints with the
landmark set at 1 year are provided in Figure 3 and
indicated no significant interaction between treat-
ment effect and time.
DISCUSSION
The salient findings of the final 2-year outcomes of
the BIOSTEMI trial can be summarized as follows.
First, BP-SES were superior to DP-EES with regard totarget lesion failure in patients undergoing primary
PCI for STEMI. The difference was driven by lower
rates of ischemia-driven target lesion revasculariza-
tion in patients treated with BP-SES compared with
DP-EES. The effect was robust and maintained after
the exclusion of historical information from the
BIOSCIENCE trial. And second, despite a significant
difference in device-oriented clinical outcomes, there
was no significant difference in the composite
patient-oriented clinical outcome between patients
treated with BP-SES and DP-EES or individual safety
endpoints such as death, myocardial infarction, and
stent thrombosis.
Different generations of DES have been defined
by technical iterations translating into improved
clinical outcomes. At 2 years, we found a significant
reduction of target lesion failure in patients treated
with BP-SES compared with DP-EES in patients un-
dergoing PCI for STEMI, driven by lower rates of
ischemia-driven target lesion revascularization in
patients treated with BP-SES. The difference
remained robust after the exclusion of historical
information and was consistent across time with no
significant interaction of treatment effect and time.
Our findings are consistent with the 3-year data of
the BIOFLOW-V (Safety and Effectiveness of the
Orsiro Sirolimus Eluting Coronary Stent System in
CENTRAL ILLUSTRATION Time-to-Event Curves for the Composite Endpoint (Target Lesion Failure) and the In-
dividual Components of the Primary Endpoint Up to 2 Years of Follow-Up
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Pilgrim, T. et al. J Am Coll Cardiol Intv. 2021;14(6):639–48.
(A) Target lesion failure, (B) cardiac death, (C) target vessel myocardial infarction, and (D) clinically indicated target lesion revascularization. Blue lines
indicate biodegradable-polymer sirolimus-eluting stents, and red lines indicate durable-polymer everolimus-eluting stents. BCI ¼ Bayesian credible interval;
BP-SES ¼ biodegradable-polymer sirolimus-eluting stent(s); DP-EES ¼ durable-polymer everolimus-eluting stent(s).
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644Subjects With Coronary Artery Lesions) trial, which
showed a lower rate of target lesion failure in pa-
tients with chronic or acute coronary syndromes
treated with BP-SES compared with DP-EES (11). In
the latter study, the difference was driven by lower
rates of both target vessel myocardial infarction and
clinically driven target lesion revascularization in
patients treated with BP-SES that emerged beyond 1
year after stent implantation. The detection of early
reinfarction in patients presenting with myocardial
infarction is challenging and may explain the
absence of a difference between the 2 treatment
arms in our trial.
In our analysis, patients with multivessel disease
seemed to particularly benefit from treatment with
BP-SES. The implantation of several stents inpatients with multivessel disease may have potenti-
ated the observed difference on a stent level.
However, given the small number of patients and the
small number of events, the finding may well be a
play of chance. Potential mechanistic explanations
for the documented differences in clinical outcomes
resort to speculation. Two particular features of the
experimental stent have been considered as an
underlying cause of differences in outcomes.
The PLLA polymer of the experimental stent
degrades over a period of at least 12 to 24 months
before exposing an amorphous hydrogen-rich, sili-
con-carbide layer designed to mitigate thromboge-
nicity and facilitate endothelialization. Although the
composition of stent strut coverage constantly
changes over time because of the degradation
FIGURE 2 Stratified Analyses of the Primary Endpoint (Target Lesion Failure) at 2 Years Across Major Subgroups
The following subgroups were pre-specified: diabetes and multivessel disease. All other subgroups were analyzed post hoc. Values are number of events/number of
patients. Bayesian log Poisson models were used to estimate rate ratios and Bayesian credible intervals (BCIs). Bayesian posterior probability is the Bayesian posterior
probability of a rate ratio <1.0 within each subgroup. Bayesian posterior probability of the interaction is the Bayesian posterior probability of a difference between the 2
subgroups. Small vessels were defined as stent diameter in any lesion #3.0 mm. Long lesions were defined as total stent length in any lesion $20 mm. Renal failure
was defined as creatinine-estimated glomerular filtration rate (eGFR) <60 ml/min using the MDRD (Modification of Diet in Renal Disease) formula. BMI ¼ body mass
index; other abbreviations as in Figure 1.
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645process of the PLLA polymer, the observed effect of a
reduction of restenosis and target lesion revascular-
ization remains constant over the follow-up duration
of 2 years. An effect of strut coverage on vascular
healing and neointimal hyperplasia appears likely
but warrants confirmation in future studies including
intravascular imaging.
At variance with the polymer matrix, the stent
platform remains stable over time and may affect
clinical outcomes. Evidence from a meta-analysis of
10 trials with different stent types suggested a
significant effect of strut thickness on the risk for
target lesion failure (19). However, it is important to
note that strut thickness between the experimental
stent and the control stent differs with stent
diameters #3.0 mm (40%), whereas the strut thick-
ness in larger stent diameters is comparable. A strat-
ified analysis according to stent diameters with a
cutoff of 3.0 mm as a surrogate to differentiate groups
according to strut thickness showed no interaction of
the treatment effect in the present study, nor in a
previous one (6). Although strut thickness alone may
not be the defining factor, the wider context of stentstrut geometry affecting flexibility and radial strength
may play a seminal role.
Interestingly, other newer generation DES also
combining very thin stent platforms with biodegrad-
able polymers were noninferior but not superior to
DP-EES with regard to device-oriented primary
composite clinical endpoints (20,21). Although these
stents share some of the defining characteristics of
newer generation DES, they differ with regard to
others, such as drug-elution kinetics, time to com-
plete degradation of the polymer, and stent strut
geometry, but also with regard to compliance of the
balloon used for stent delivery.
A final important finding of our study is that up to
one-half of all events within 2 years after myocardial
infarction were unrelated to the stent implanted
during the index procedure. This finding is consis-
tent with 5-year data from the COMFORTABLE
AMI (Biolimus-Eluting Stents With Biodegradable
Polymer Versus Bare-Metal Stents in Acute Myocar-
dial Infarction) trial and the EXAMINATION
(Everolimus-Eluting Stents Versus Bare-Metal Stents
in ST-Segment Elevation Myocardial Infarction) trial
FIGURE 3 Time-to-Event Curves for Target Lesion Failure and Its Individual Components With a Landmark Set at 1 Year
(A) Target lesion failure, (B) cardiac death, (C) target vessel (TV) myocardial infarction, and (D) clinically indicated target lesion revascularization. Blue lines indicate
biodegradable-polymer sirolimus-eluting stents, and red lines indicate durable-polymer everolimus-eluting stents. BCI ¼ Bayesian credible interval; BPP ¼ Bayesian
posterior probability; TLR ¼ target lesion revascularization.
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646and highlights the relative importance of secondary
prevention to mitigate disease progression versus
device performance (2,3).
Five-year data from the BIOSCIENCE trial sug-
gested a higher all-cause mortality among patients
treated with BP-SES compared with DP-EES (6).
Although the difference in the BIOSCIENCE trial
emerged as early as 2 years (22), we documented
comparable rates of all-cause mortality between
patients treated with BP-SES and DP-EES in the
BIOSTEMI trial at 2 years.
Acute STEMI is the flagship indication for
PCI. The BIOSTEMI trial is the first head-to-head
comparison of 2 newer generation DES in patients
undergoing primary PCI for acute myocardial infarc-
tion. In a field of stent comparisons dominated bynoninferiority trials, the BIOSTEMI trial stands out by
its superiority design, demonstrating a significant
difference between 2 contemporary DES. A significant
difference between newer generation DES may have
clinically relevant implications for routine clinical
practice.
STUDY LIMITATIONS. First, the study was powered
to show a significant difference between the experi-
mental arm and the control arm with regard to a
composite clinical endpoint. Differences in individual
clinical endpoints need to be interpreted with
caution. However, in contrast to the primary
endpoint data at 1 year, 2-year data show a significant
difference between the 2 treatment arms not only
using Bayesian statistics incorporating a historical
PERSPECTIVES
WHAT IS KNOWN? The long-term clinical outcomes of pa-
tients with acute STEMI undergoing primary PCI are determined
by the safety and efficacy profile of the newest generation DES.
WHAT IS NEW? BP-SES are superior to DP-EES with respect to
target lesion failure at 2-year follow-up among patients under-
going primary for STEMI. The difference is driven by lower rates
of ischemia-driven target lesion revascularization.
WHAT IS NEXT? The use of biodegradable-polymer DES may
further improve clinical outcomes in patients with acute STEMI
undergoing primary PCI.
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647prior from the BIOSCIENCE trial but also when
analyzed as an independent clinical trial.
Second, follow-up was limited to 2 years and did
not expand well beyond the time of polymer degra-
dation. Differences in the safety profile of the 2 stents
may emerge only after discontinuation of dual-
antiplatelet therapy. It is important to note that the
low adherence to dual-antiplatelet treatment at 2
years in the BIOSTEMI trial, although reflecting
current international guidelines, was considerably
lower compared with previous STEMI trials (2,3).
Third, follow-up at 2 years was available in 94% of
patients. Because provisional study inclusion was
possible in unconscious patients by consent by proxy,
the majority of patients refusing follow-up dropped
out early.
And finally, study participants and physicians were
not blinded to treatment allocation.
CONCLUSIONS
The final 2-year outcomes of the BIOSTEMI trial
demonstrated superiority of BP-SES versus DP-EES
with respect to target lesion failure in patients un-
dergoing primary PCI for STEMI. The difference was
robust after the exclusion of historical information
from the BIOSCIENCE trial and driven by lower rates
of target lesion revascularization in patients treated
with BP-SES compared with DP-EES.
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